Categories
Change Password!
Reset Password!
With pioglitazone showing significant reductions in inflammation alongside its established role in managing insulin resistance, physicians may soon have a powerful tool to address both metabolic and inflammatory components of PCOS.
A randomized controlled trial published in ‘Reviews in Clinical Medicine' journal proved pioglitazone to significantly ease inflammation in women with polycystic ovarian syndrome (PCOS), challenging the standard treatment approaches and potentially altering the course of care for millions of women affected by this common hormonal disorder.
This inference was drawn from comparing the effects of 3 well-known treatments—pioglitazone, cyproterone compound (CC) combined with spironolactone (SP), and metformin—on key inflammatory markers in PCOS. The trial included 90 women diagnosed with PCOS, randomly assigned to one of three treatment groups for 90 days:
Serum levels of inflammatory markers—high-sensitivity C-reactive protein (hs-CRP), C3, and C4—were measured before and after the treatment period. As found, the group receiving pioglitazone showed a significant decrease in inflammatory markers levels (p<0.05). This demonstrates pioglitazone’s strong anti-inflammatory effect, making it a potential dual-purpose treatment for both insulin resistance and inflammation in PCOS.
The group receiving CC-SP showed a significant increase in inflammatory markers. Both hs-CRP and C3 levels rose suggestively, highlighting the potential inflammatory risks of this treatment combination. While effective for metabolic control, metformin did not significantly alter the levels of all three markers, suggesting its limited effect on inflammation in PCOS. Pioglitazone’s ability to significantly reduce inflammation in women with PCOS makes it a compelling treatment option, particularly for those struggling with both metabolic and inflammatory symptoms.
Reviews in Clinical Medicine
Comparison of the Effects of Cyproterone Compound-Spironolactone, Metformin and Pioglitazone on Serum Levels of High Sensitivity C-Reactive Protein and Complement System in Polycystic Ovarian Syndrome: A Randomized Double-blind Clinical Trial
Mesbah Shams et al.
Comments (0)